

Assessment of asthma diagnosis and management in an academic primary clinic

Hyo-bin Um MD MPH, Sana Rashid DO, Jared Sapin MD, Yawen Zhang DO PhD, and Piyumika de Silva MD **Department of Internal Medicine, Rutgers New Jersey Medical School**

BACKGROUND

- Asthma is a chronic inflammatory airway disease characterized by hyperresponsiveness¹
- The 2019 Global Initiative for Asthma (GINA) guideline recommends changes in asthma management²
- The most noteworthy change is prescribing a lowdose inhaled corticosteroid (ICS)-formoterol inhaler (i.e. Symbicort), rather than a short-acting beta agonist (SABA), for as-needed therapy regardless of severity
- An alternative is SABA paired with an ICScontaining inhaler
- In our experience at academic clinic, patients' reported diagnosis of asthma is often unconfirmed and Pulmonary Function Tests (PFTs) are difficult to access in the electronic medical record (EMR)

METHODS

- A total of 300 patients who visited our clinic in January 2022 were randomly selected
- Their current and past visits were reviewed in the \bullet EMR
- Patients were included in the analysis if there was \bullet a documented problem of "asthma" or "asthma/chronic obstructive pulmonary disease (COPD)."
- The following measures were collected:
 - 1) documentation of PFT results or an order \bullet for PFTs if absent in the EMR
 - 2) current inhaler prescriptions (i.e., SABA) \bullet alone, ICS-formoterol, and SABA + ICS combination).

Out of the 300 patients, 40 (13.3%) had "asthi (n=34) or "asthma/COPD" (n=6) documented

- 14 (35.0%) had PFTs available in the EMR
 - only two included a bronchodilator test
 - six demonstrated an obstructive airway disease
- When a PFT was available in the EMR, it was documented only 42.9% of the time
- When there was no PFT, it was ordered 30.8% the time
- 30.0% were on ICS-formoterol as one of their treatments, 27.5% SABA and ICS combination 32.5% SABA only

CONCLUSIONS

- Our study showed that PFTs were not documented about half of the time despite being available in the EMR
- If there was no PFT available, it was ordered than a third of the time
- About one-third of the patients were treated with SABA only, which is inconsistent with the GINA guideline
- Further studies, including quality improvement project, are indicated with a bigger patient sample



RESULTS

	Table 1. Characteristics of patients with asth asth asthma/COPD included in the analysis			
	Characteristics	No.	% or	
st	Age, years (median)	40	52	
ay	Gender, Female	27	67.5	
	Race & Ethnicity			
	Black or African American	24	60.0	
	Hispanic or Latino	16	40.0	
% of	Translation Service Required, Yes	10	25.0	
	Insurance			
r	Insured	32	80.0	
n, and	Charity Care	5	12.5	
	Uninsured	3	7.5%	
	Smoking Status			
	Current Smoker	11	27.5	
	Never Smoker	21	52.5	
less	Former Smoker	8	20.0	
	BMI (median)	40	34	
	Residency in Newark	32	80.0	

REFERENCES

- Asthma and Allergy Foundation of America. Asthma. Electronically accessed at https://www.aafa.org/asthma.aspx
- 2. Global Strategy for Asthma Management and Prevention (2019 Update). Global Initiative for Asthma. Electronically accessed at https://ginasthma.org/wp- content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf



